Business Context and Reporting Period
Company: Helius Medical Technologies, Inc. (Note: Input metadata referenced "Solana Co," but the filing text identifies the registrant as Helius Medical Technologies, Inc., trading under symbol HSDT).
Reporting Period: Fiscal year ended December 31, 2024.
Business Overview: Helius is a neurotechnology company developing non-implantable technologies to treat neurological conditions. Its primary product is the Portable Neuromodulation Stimulator (PoNS), a device delivering mild electrical stimulation to the tongue to treat gait and balance deficits. The device is FDA-cleared in the U.S. for Multiple Sclerosis (MS) and authorized in Canada for MS, mild-to-moderate Traumatic Brain Injury (mmTBI), and stroke. The company is currently conducting clinical trials for stroke indications in the U.S.
Key Financial Metrics
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Total Revenue | $520 | $644 |
| Cost of Revenue | $582 | $583 |
| Gross Profit (Loss) | $(62) | $61 |
| Operating Expenses | $13,841 | $12,489 |
| Net Loss | $(11,742) | $(8,850) |
| Cash and Cash Equivalents (Year End) | $1,088 | $5,182 |
| Working Capital | $1,261 | $5,559 |
| Accumulated Deficit | $(171,699) | $(159,957) |
Liquidity: The company reported a net decrease in cash of $4.1 million for 2024. As of December 31, 2024, cash and cash equivalents totaled approximately $1.1 million. Management states existing resources are sufficient to fund operations into the second quarter of 2025.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by $124,000 (19%) to $520,000. U.S. product sales dropped significantly ($181k vs $324k in 2023) due to the termination of the Patient Therapy Access Program (PTAP) and temporary cash pay pricing. Canadian sales increased slightly ($295k vs $281k).
- Increased Losses: Net loss widened by $2.9 million to $11.7 million, driven by higher operating expenses ($13.8M vs $12.5M) and a decrease in nonoperating income.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose by $847,000, primarily due to a $700,000 increase in stock-based compensation. R&D expenses increased by $717,000 due to clinical trial costs.
- Derivative Liability: The company recognized a $2.98 million gain from the change in fair value of derivative liability (warrants), partially offsetting the operating loss.
- Manufacturing Transition: Completed the transition of PoNS device manufacturing from Key Tronic Corporation to Minnetronix, Inc. in Q4 2024.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The independent auditor has included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern due to recurring losses and an accumulated deficit. Additional financing is required beyond Q2 2025.
- Reimbursement Status: CMS assigned HCPCS codes effective April 2024. However, final Medicare reimbursement rates were set significantly lower than the company's list price (Controller: ~$532; Mouthpiece: ~$2,963). The company plans to challenge these rates. Broad commercial payer coverage is not expected for at least 24 months.
- Regulatory Outlook: The company is on track to submit an FDA application for stroke indications in Q2 2025, with approval targeted for end of 2025. Enrollment for stroke trials exceeded targets (128 participants by year-end).
- Stock Listing Risk: The company received notice of non-compliance with Nasdaq minimum bid price and stockholders' equity requirements. An appeal hearing was held in March 2025; delisting remains a risk pending the panel's determination.
- Subsequent Event: In January 2025, the company executed a warrant exercise inducement generating approximately $3.7 million in gross proceeds ($3.4 million net) to extend its cash runway.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.1 million year-end cash balance plus the $3.4 million subsequent proceeds to fund operations through Q2 2025 and the stroke trial completion.
- Reimbursement Rates: Confirm the finality of CMS reimbursement rates and the status of any appeals or negotiations with commercial payers, as current rates are a fraction of the list price.
- Nasdaq Compliance: Monitor the outcome of the Nasdaq Hearing Panel regarding the minimum bid price and equity requirements to assess delisting risk.
- Revenue Concentration: Note that two customers accounted for 72% of net product sales in 2024, creating significant concentration risk.
- Derivative Liability: Review the valuation assumptions for the warrant liability, which contributed a significant non-cash gain to the income statement.